Les métastases de I'uvée: étude statistique de 133 cas

Beati, D.; Zografos, Léonidas; Egger, Emmanuel; Chamot, Line; Bercher, L.

doi:10.1055/s-2008-1035554

Cited by 5 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example 100% of patients with smaller tumors and without retinal detachment but only 30% of patients with larger tumors and a retinal detachment had an improvement of VA after RT [17]. The median survival time of all patients with choroidal metastases is short and ranges between 4-12 months [18,[27][28][29].This corresponds well with our results. It is widely accepted that breast cancer patients with choroidal metastases survive significantly longer than patients with other primary tumors [6,7,20].…”

Section: Discussionsupporting

confidence: 90%

“…So far described were cataract, keratopathy, retinopathy, neovascularisation of the iris, and opticus neuropathy [5,6,21,[34][35][36][37]. Typically neither the side effects are described in most publications nor is the good tolerance of the therapy emphasized [27,35,38]. One reason could be that 30-50% of the patients died after 5-7 months and therefore the late side effects did not appear.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radiotherapy of Choroidal Metastases in Patients with Disseminated Cancer

Bottke

Wiegel²,

Kreusel³

et al. 2000

Oncol Res Treat

View full text Add to dashboard Cite

Background: >Choroidal metastasis is the most common ocular tumor, in most cases related to breast and lung cancer. Radiotherapy (RT) mostly is the therapy of choice. However, there is a lack of data about the results of uniformly, prospective treated patients. Patients and Methods: Between November 1994 and September 1997, 37 patients with 49 metastatic eyes were enrolled into the study. 25 patients (68%) had unilateral and 12 patients (32%) had bilateral metastases. 21 patients had breast cancer as primary tumor, 12 patients lung cancer, and 4 patients other tumors. 3 patients were excluded from analysis, 34 patients with 46 involved eyes were available for analysis. 29 of those patients had symptomatic metastases, 5 patients had asymptomatic choroidal metastases. RT was performed with bi- or unilateral asymmetric fields, total dose was 40 Gy with a single dose of 2 Gy, 5 fractions per week. 12 patients (35%) had a chemotherapy following RT due to diagnosis of general tumor progression. Endpoints of the study were visual acuity (VA), local tumor control, survival, and side effects. Results: The median follow up was 6 months, 22 out of 34 patients died of metastatic disease. In 17 of symptomatic eyes (53%) an increase of VA and in 11 of symptomatic eyes (34%) a ‘no change’ was achieved. The local tumor control rate after 18 months was 83%. One patient with asymptomatic metastasis (1/14 eyes) developed symptoms until death. The median survival time was 15 months. Altogether, in 2 patients late side effects (6%) were observed (1 patients with bilateral retinopathy, 1 patient with optic nerve atrophy). Conclusions: RT with 40 Gy is highly effective in the treatment of symptomatic and asymptomatic choroidal metastases, VA was stable or improved in almost 90% of treated eyes. The rate of side effects is low.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionmentioning

confidence: 99%

Radiotherapy of Choroidal Metastases in Patients with Disseminated Cancer

Bottke

Wiegel²,

Kreusel³

et al. 2000

Oncol Res Treat

View full text Add to dashboard Cite

show abstract

“…Other similar classifications have been proposed [57,58]. Beati et al [6] noted among 133 patients, 73 of whom suffered from breast cancer, 97 cases (75%) with scotoma (16%). phosphenes (11%).…”

Section: Symptomatology According To the Location Of The Métastasésmentioning

confidence: 69%

“…Rarely, metastases will be found before the primary is located, when a breast cancer is found by further examination of the patient [4], Raymond et al [5] found that between 12 and 30% of the ocular metastases are the first sign in the evolution of breast cancer. In 6% of the patients of Beati et al [6], ophthal mologic metastases were the first sign of an unsuspected breast carcinoma. The metastases can be present simultaneously with the primary, but the large majority of the metastases occur af ter months or years, even decades.…”

Section: Mammakarzinom • Orbitalmetastasen • Metastasen Des Augesmentioning

confidence: 89%

See 1 more Smart Citation

Breast Cancer and the Eye

Debois¹,

F²

1996

Oncol Res Treat

View full text Add to dashboard Cite

Breast cancer has the well-known propensity to metastasize to almost any organ, giving rise to an almost unlimited variability of clinical syndromes. Ophthalmic metastases may become a part of such a pattern. Orbital and ocular metastases are not a rare event within the clinical evolution of a breast cancer, accounting for about 2-10%. Their diagnosis is usually simple and involves only clinical and noninvasive methods. Radiotherapy is the treatment of choice in most of these situations and should obviate the need for exenteration. Radiotherapy is always rewarding, enhances the comfort of the patient by preventing further loss of vision and even promotes his recuperation. Radiotherapy plays an important role in the relief of the symptoms and for the patient’s well-being. Local curability is high, but probably has no influence on the course of the metastatic disease.

show abstract